Hamburg said that the drug does not meaningfully reducing the size of tumors, nor help the patients live longer. The drug was also exposing patients to serious side effects, such as hemorrhaging and severe high blood pressure.
As of right now, Avastin will remain on the market as treatment for other cancers. However, insurers might not continue paying for the drug which would put it out of reach for post patients, as it costs around $88,000 a year.
Snyder and Wenner, P.C.